drugset
drugset / Trial / NCT04110028

Nicotinamide Riboside in Hospitalized Patients

NCT04110028 ↗

Phase 1/2 Completed 57 enrolled Oslo University Hospital ChromaDex, Inc. · collab
RandomizedSequentialQuadruple-blindSupportive care

Summary

Patients will receive oral nicotinamide riboside or placebo and clinical and paraclinical outcome will be determined

Timeline

Start
2019-10-01
Primary completion
2022-12-01
Completion
2023-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Nicotinamide riboside Small molecule 250 mg Oral
Subject Nicotinamide riboside Small molecule 500 mg Oral
Subject Nicotinamide riboside Small molecule 1000 mg Oral
Subject Nicotinamide riboside Small molecule 2000 mg Oral

Indications

No indication recorded.